Designing of Heterocyclic Compounds as Promising VEGFR2 Tyrosine Kinase Inhibitors: An In silico Analysis

Abstract

Cancer is the most dangerous disease a human race battle with. Due to which, it is necessity of medicinal chemist to evaluate possible scenario to fight against this disease. The heterocyclic compounds have shown to possess intrinsic diversity and several physicochemical properties. Thus, investigation of newer and potential compounds for their activity to resist several malignancies. The present study aims to derivatize four different heterocyclic compounds. The number of members present in the ring has importance in heterocyclic compounds. Thus, the six-member ring containing pyrimidine, six-member ring fused with five-member ring in indole, bi-penta membered ring containing thiadiazole, and one six-member and a penta membered ring containing triazoles have been used in the present study. In search of potential anticancer drugs, several molecules were evaluated and checked for their potency to interact with a cancer target enzyme Vascular endothelial growth factor receptor 2 (VEGFR2). This study involves detailed in-silico analysis of several compounds and indicates compounds having the potential ability to resist these enzymes and hence the anticancer agent.